Copyright
©The Author(s) 2017.
World J Gastroenterol. Feb 14, 2017; 23(6): 1051-1058
Published online Feb 14, 2017. doi: 10.3748/wjg.v23.i6.1051
Published online Feb 14, 2017. doi: 10.3748/wjg.v23.i6.1051
Group A (n = 254) | Group B (n = 307) | P value | |
Sex | |||
Male | 214 (84) | 260 (85) | 0.907 |
Female | 40 (16) | 47 (15) | |
Age (yr), median (range) | 64 (39-81) | 66 (41-86) | < 0.001 |
Baseline clinical TNM-stage | |||
I | 119 (47) | 155 (50) | 0.39 |
II | 66 (26) | 88 (29) | 0.50 |
III | 69 (27) | 64 (21) | 0.09 |
Treatment for primary ESCC | |||
Surgery | 84 (33) | 124 (40) | 0.079 |
Endoscopic resection | 77 (30) | 113 (37) | 0.010 |
Chemoradiotherapy | 93 (37) | 70 (23) | 0.001 |
Follow-up period | |||
Median months (range) | 60 (13-145) | 67 (12-107) | 0.150 |
- Citation: Morimoto H, Yano T, Yoda Y, Oono Y, Ikematsu H, Hayashi R, Ohtsu A, Kaneko K. Clinical impact of surveillance for head and neck cancer in patients with esophageal squamous cell carcinoma. World J Gastroenterol 2017; 23(6): 1051-1058
- URL: https://www.wjgnet.com/1007-9327/full/v23/i6/1051.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i6.1051